Quadrature Capital Ltd Grows Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Quadrature Capital Ltd lifted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 129.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,432 shares of the medical instruments supplier’s stock after purchasing an additional 12,654 shares during the quarter. Quadrature Capital Ltd’s holdings in LeMaitre Vascular were worth $1,484,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. YHB Investment Advisors Inc. purchased a new stake in shares of LeMaitre Vascular in the 1st quarter valued at approximately $36,000. SRS Capital Advisors Inc. raised its position in LeMaitre Vascular by 325.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 524 shares during the period. Envestnet Portfolio Solutions Inc. acquired a new position in LeMaitre Vascular in the first quarter valued at about $206,000. Whitegate Investment Counselors Inc. acquired a new position in shares of LeMaitre Vascular in the 1st quarter worth approximately $216,000. Finally, Lindenwold Advisors INC purchased a new position in shares of LeMaitre Vascular during the first quarter worth $222,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Down 0.5 %

LeMaitre Vascular stock traded down $0.41 during trading on Friday, reaching $85.83. The stock had a trading volume of 138,204 shares, compared to its average volume of 142,019. LeMaitre Vascular, Inc. has a 52-week low of $44.27 and a 52-week high of $91.76. The stock has a market cap of $1.93 billion, a PE ratio of 56.84, a P/E/G ratio of 2.63 and a beta of 0.89. The business has a 50 day moving average price of $81.97 and a 200 day moving average price of $70.71.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.05. The business had revenue of $53.48 million during the quarter, compared to analysts’ expectations of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.27 EPS. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.75%. The ex-dividend date was Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday. Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and raised their price objective for the company from $59.00 to $75.00 in a research note on Friday, April 26th. Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a report on Friday, May 31st. Roth Mkm reiterated a “buy” rating and set a $100.00 target price on shares of LeMaitre Vascular in a report on Friday, May 31st. Finally, JMP Securities boosted their price target on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research note on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average target price of $77.57.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares in the company, valued at $168,944,956.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 8,000 shares of LeMaitre Vascular stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the sale, the chief executive officer now owns 2,079,128 shares in the company, valued at approximately $156,558,338.40. The disclosure for this sale can be found here. Insiders sold a total of 127,437 shares of company stock worth $10,076,242 over the last 90 days. 10.79% of the stock is owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.